Bundibugyo Ebola Evades 3.5m Vaccines

More than 1,000 suspected infections. Over 240 deaths. Health workers trying to operate in an active war zone. And no approved vaccine for the virus driving the outbreak. The emergency in eastern Congo has exposed a weakness in Ebola preparedness: the vaccines and treatments the world has ready are aimed at a different species of the virus.

A Vaccine Made For The Wrong Virus

The virus spreading in the DRC's Ituri Province is Bundibugyo Ebola, first identified in Uganda in 2007. It has caused only two known outbreaks before, both small enough to remain largely outside international attention. That is exactly why the gap exists. After the 2014 West Africa epidemic, vaccine development focused on the Zaire species of Ebola.

Vaccines teach the immune system to recognise a surface protein on a virus, known as a glycoprotein. Merck's Ervebo, the vaccine used against recent Zaire outbreaks, trains the body to recognise Zaire's glycoprotein. Bundibugyo's version differs by roughly 30% in its genetic sequence. That is enough to make protection uncertain.

The WHO brought experts together in late May and concluded that evidence on cross-protection is "very limited and insufficient". A small primate study suggested partial survival after the Zaire vaccine, but all vaccinated animals still became ill. The approved antibody treatments, Inmazeb and Ebanga, are also not expected to work. The global stockpile contains more than 3.5 million doses of Ervebo, all built for a pathogen that is not the one now circulating.

The Response Is Already Behind

The WHO declared the outbreak a Public Health Emergency of International Concern on 17 May, only two days after the DRC officially announced it. That speed says less about institutional efficiency than about how far the virus had moved before confirmation. By the time laboratories identified Bundibugyo, the numbers were already large. As of early June, about 282 cases had been confirmed in laboratories, with 42 deaths, while suspected cases had passed 1,000.

Conflict makes the health response far harder. The M23 rebel group controls cities in neighbouring provinces, including Goma, a city of more than one million people on the Rwandan border. ADF fighters killed seven people in Beni, one of the areas affected by the outbreak. Hundreds of diagnostic samples remain untested. Uganda has confirmed nine cases and closed its border.

Two vaccine candidates are being pushed forward. Oxford's ChAdOx1 platform, adapted from the AstraZeneca Covid vaccine technology, could produce trial doses in two to three months. A second candidate from IAVI, which uses a harmless livestock virus to carry Bundibugyo proteins into the body, needs seven to nine months. Neither has been tested in humans. Gavi has committed $50 million to speed up production once there is evidence that a candidate works.

What Europe Found It Cannot Do

One confirmed Ebola case has reached EU soil: a US healthcare worker admitted to Berlin's Charité hospital on 20 May. An Italian MSF surgeon evacuated to Rome's Spallanzani Institute tested negative. Two suspected cases in Brazil turned out to be meningitis and malaria. The ECDC puts the risk to European citizens at very low.

For Malta, the immediate risk is not the point. The more serious issue is what the outbreak says about Europe's post-Covid machinery. HERA, the EU agency created to secure vaccines and medical supplies during emergencies, built joint procurement systems and 22 strategic stockpiles across member states. That model worked for monkeypox in 2022 because an approved vaccine already existed. For Bundibugyo, there is nothing to buy. The EU has instead allocated €7.4 million to the WHO for clinical trials, paying into research because it cannot solve the shortage through procurement.

National responses are still fragmented. Italy issued a five-level risk classification with mandatory health declarations for arrivals from the DRC and Uganda. Germany relies on seven specialised isolation stations. France has reinforced surveillance at Mayotte but has no unified quarantine protocol aligned with other member states.

The world spent billions preparing for the last Ebola emergency, not this one. Bundibugyo was a "commercially uninteresting" strain, as German health experts put it, until rarity stopped being a comfort. Whether this outbreak leads to serious investment in broad-spectrum Ebola vaccines, or is forgotten once the emergency fades, will say more about pandemic preparedness than any EU framework on paper.